Share This

Public company info - Brii Biosciences Limited , 02137.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Brii Biosciences Limited, 02137.HK - Company Profile
Chairman Zhi HONG
Share Issued (share) 706,000,000
Par Currency U.S. Dollar
Par Value 5.0E-6
Industry Biotechnology
Corporate Profile Business Summary: The group is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. Performance for the year: For the years ended December 31, 2019 and 2020, the group had a loss of RMB521.0 million and RMB1,283.5 million, respectively. Business Review The group is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have significant public health burdens in China and worldwide. The group is achieving this vision with a business model combining internal discovery and in-licensing. Infectious diseases are a leading cause of death worldwide. However, for many infectious diseases with significant public health burdens there are a limited number of available therapeutics and companies dedicated to developing these therapeutics, resulting in a significant unmet need. HBV-related diseases, the global HIV pandemic and the unprecedented outbreak of the COVID-19 pandemic each underscore the threat posed by infectious diseases to society and economies and the need for companies dedicated to developing therapeutics that cure, prevent or treat such diseases as well as the need to respond to both anticipated and unanticipated public health crises. For example, approximately 73 million people in China were HBV infected as of 2019, which accounted for about one-third of the total HBV patient population worldwide, translating into a total healthcare cost of RMB80 billion to RMB120 billion per year in China for HBV-related diseases, according to Frost & Sullivan. In 2019, HIV infection affected 39.1 million people globally, of which 1.7 million people became newly infected. Similarly, over the past 15 years, gram-negative bacteria related infections have accounted for about 70% of all clinical infections in China, according to Frost & Sullivan. It is also estimated by the World Bank that MDR gram-negative bacterial infections will cause a global GDP loss of US$1 trillion to US$3.4 trillion by 2030. As of the end of March 2021, the COVID-19 pandemic had resulted in over 2.7 million related deaths globally, with a significant impact on society and a global GDP loss of US$3.8 trillion in 2020, according to the World Bank. The group is currently developing a functional cure for chronic HBV infections, which has a disproportional health impact in China. In response to the global HIV pandemic, the group discovered and are developing a long-acting, once-weekly (QW) single tablet regimen (STR) for HIV patients with an initial focus in the United States. The group is also developing broad spectrum antibiotics to treat MDR/XDR gram-negative bacterial infections, both of which have a disproportional health impact in China. In response to the unprecedented global COVID-19 pandemic, and consistent with the group’s commitment to public health matters, The group is developing the group’s neutralizing antibody cocktail therapy for the treatment of COVID-19. Furthermore, The group is developing innovative therapies to address CNS disorders, such as postpartum depression (PPD) and major depressive disorder (MDD). Depression is frequently observed not only in patients with CNS diseases but also with other chronic diseases. Furthermore, the COVID-19 pandemic, accompanied with resulting societal disruption and economic uncertainties, has exacerbated the prevalence of mood disorders globally. The global incidence of PPD reached 18.9 million in 2019. the group believe that there is a significant unmet need for new therapies that can provide rapid relief and profound and sustained therapeutic effect against these disorders. The group’s focus on significant infectious diseases and CNS diseases is reflected in how the group have built the group’s portfolio of development programs. As shown in the group’s product pipeline below, the group have built a pipeline of more than 10 innovative product candidates that focus on infectious diseases and CNS diseases and range from preclinical to clinical stage programs, and the group have options to in-license up to five additional innovative programs from the group’s license partners. the group developed the group’s product pipeline through (i) utilizing the group’s in-house research and development (R&D) capabilities to discover and develop the group’s own innovative products and (ii) establishing collaborative licensing arrangements with the group’s carefully selected strategic partners to in-license the Greater China rights to their important assets, under which the group will lead the clinical development of such assets in China and also play an integral role in the global development of such assets. Prospects: The group’s mission is to bring innovation and insight to deliver transformative therapies which address critical public health needs and establish ourselves as a leader in the infectious disease and other target markets. the group plan to execute the following strategies to fulfill the group’s mission: • Advance BRII-179/BRII-835 combined, the group’s therapeutic vaccine and siRNA combination therapy designed to provide a functional cure for HBV infection in Greater China. • Advance the group’s HIV, PPD and other therapies for diseases with considerable unmet needs. • Expand the group’s pipeline of programs through the group’s in-house discovery and strategic in-licensing of complementary candidates and explore value creation opportunities for the group’s assets. • Continue to scale up the group’s organization in China and the United States as the group’s business develops.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.